PREDICTIVE MARKERS OF TREATMENT RESPONSE TO 5-FU AND GEMCITABINE IN PANCREATIC CANCER
John Farrell(Peoria campus of the University of Illinois System), Hany Elsaleh(Sir Charles Gairdner Hospital), Marius van Rijnsoever, Al B. Benson(Northwestern University), John R. Mackey(University of Alberta), William F. Regine(University of Kentucky), Raymond Lai(University of Alberta), Paul Schaeffer(Universidad La Salle), J. S. Macdonald(SWOG Cancer Research Network), K. De Winter(Radiation Oncology Institute), Christopher G. Willett
Cited by 0
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Hepatobiliary Cancers
|Journal of the National Comprehensive Cancer Network|2009|2.3k